I was first drawn to medicine because I wanted to help people. I chose hematology and oncology because they are rapidly evolving fields—through their advances, I can treat people using the newest therapies. More importantly, I can care for people by forging meaningful relationships with them.
I treat each patient as a partner, and together, we work toward a common goal. Communication with my patients and their caregivers is essential to providing the best care. I also prioritize providing my patients with access to clinical trials.
At Perlmutter Cancer Center, my colleagues and I approach cancer treatment as a collaboration between specialties. We offer patients the most current clinical trials and we strive to provide as much support as possible for patients and families during such a difficult time.
My clinical and research interest is gastrointestinal cancers, with a focus on liver and biliary cancer, pancreatic cancer, and gastric cancer. Currently, I am studying whether radiation therapy in combination with immunotherapy is an effective treatment for pancreatic cancer.
Conditions and Treatments
- abdominal tumor
- anal cancer
- biliary cancer
- colon cancer
- colorectal cancer
- esophageal cancer
- gallbladder cancer
- gastrointestinal cancer
- liver cancer
- pancreatic cancer
- rectal cancer
- stomach cancer
This provider accepts the following insurance plans.
- Railroad Medicare
Senior Whole Health
- Senior Whole Health
- WellCare Medicare
A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.
A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
World journal of gastroenterology : WJG. 2022 Jun 21; 28(23):2561-2568
JCO oncology practice. 2021 Nov 08; OP2100629
Liver cancer. 2021 Feb ; 10(1):38-51